Peter Mclaughlin, MD

home / authors / peter-mclaughlin-md

Articles

April 1st 2005

The indolent non-Hodgkin's lymphomas constitute a heterogeneous group of lymphoproliferative disorders usually associated with relatively prolonged survival. They are categorized based on pathologic and cytologic features, and, with few exceptions [1], they are almost exclusively of B-cell origin.

Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphomas

Andreas H. Sarris, MD, PhD;Alexandria T. Phan, MD;A. Goy, MD;Jorge Romaguera, MD;Fredrick B. Hagemeister, MD;Maria A. Rodriguez, MD;Peter Mclaughlin, MD;Barbara Pro, MD;L. Jeffrey Medeiros, MD;Barry Samuels, MD;Ofie Mesina, RN;A. W. Bleyer, MD;Fernando Cabanillas, MD

August 1st 2002

Because irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity, we investigated its activity in relapsed or refractory non-Hodgkin’s lymphomas (NHLs). Irinotecan at 300 mg/m² IV was administered every 21 days with intensive loperamide management of diarrhea.

The Role of Mitoxantrone in Non-Hodgkin’s Lymphoma

Peter Mclaughlin, MD

April 1st 2002

Dr. Armitage is an experienced investigator in both lymphoma research and marrow/stem cell transplantation. As such, he is ideally suited to comment on the attributes of mitoxantrone (Novantrone) in the treatment of malignant lymphoma.

Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphoma

Andreas H. Sarris, MD, PhD;Jorge Romaguera, MD;Fredrick B. Hagemeister, MD;Maria A. Rodriguez, MD;Peter Mclaughlin, MD;Barbara Pro, MD;Anas Younes, MD;Ofie Mesina, RN;Fernando Cabanillas, MD;L. Jeffrey Medeiros, MD;Barry Samuels, MD

July 1st 2001

Irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity. Various schedules and doses have been studied, and major complications were delayed diarrhea and

Update on the Management of Primary CNS Lymphoma

Peter Mclaughlin, MD

February 1st 2000

Primary central nervous system (CNS) lymphoma is a non-Hodgkin’s lymphoma restricted to the nervous system. The incidence of this lymphoma is rising in the immunocompetent population but may be decreasing in patients

Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas

Peter Mclaughlin, MD;Christine A. White, MD;A. J. Grillo-Lopez, MD;David G. Maloney, MD, PhD

December 1st 1998

Rituximab (IDEC-C2B8 [Rituxan]) is a chimeric anti-CD20 monoclonal antibody (MoAb) that was recently approved by the FDA for the treatment of patients with low-grade or follicular B-cell non-Hodgkin’s lymphoma. Its potential efficacy in other B-cell malignancies is currently being explored. This article reviews the mechanisms of action of rituximab, as well as preclinical data and results of the clinical trials that led to its approval. Also discussed are the mechanics of administering rituximab on the recommended weekly ´ 4 outpatient schedule. Finally, the article describes ongoing and planned trials of rituximab in other dosage schedules, in other B-cell neoplasms, and in conjunction with chemotherapy. As the first MoAb to gain FDA approval for the treatment of a malignancy, rituximab signals the beginning of a promising new era in cancer therapy. [ONCOLOGY 12(12):1763-1770, 1998]